Aitchison K. J. & Kerwin R. W. (1997) Cost-effectiveness of clozapine: a UK clinic-based study. British Journal of Psychiatry, 171, 125–130.
Bindman J., Glover G., Goldberg D., et al (2000) Expenditure on mental health care by English health authorities: a potential cause of inequity. British Journal of Psychiatry, 177, 267–274.
Carr-Hill R. A., Hardman G., Martin S., et al (1994) A Formula for Distributing NHS Revenues Based on Small Area Use of Hospital Beds. York: Centre for Health Economics, University of York.
Geddes J., Freemantle N., Harrison P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 1371–1376.
Hayhurst K. P., Brown P. & Lewis S. (2002) The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. Journal of Psychopharmacology, 16, 169–175.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE.
National Schizophrenia Fellowship (2000) A Question of Choice. London: NSF.
Purcell H. & Lewis S. (2000) Postcode prescribing in psychiatry: clozapine in an English county. Psychiatric Bulletin, 24, 420–422.
Thompson A. J. (1999) Inequality in the availability of expensive treatments. Journal of the Royal College of Physicians of London, 33, 448–449.